Phase 1b Study on AT-100 Intervention (rhSP-D) in Preterm Neonates at High Risk for Development of Bronchopulmonary Dysplasia (BPD) - Trial NCT04662151
Access comprehensive clinical trial information for NCT04662151 through Pure Global AI's free database. This Phase 1 trial is sponsored by Airway Therapeutics, Inc. and is currently Not yet recruiting. The study focuses on Bronchopulmonary Dysplasia. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Airway Therapeutics, Inc.
Timeline & Enrollment
Phase 1
Apr 01, 2021
Feb 01, 2022
Primary Outcome
Safety and tolerability of AT-100
Summary
The purpose of this study is to determine if an investigational drug, AT-100, can reduce the
 occurrence of Bronchopulmonary Dysplasia (BPD) in babies born premature, as compared to
 babies born premature who receive an air-sham alone.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04662151
Non-Device Trial